Used in the treatment of soft tissue sarcomas, particularly in patients who are not candidates for curative surgery or radiation. It functions by binding to the platelet-derived growth factor receptor alpha (PDGFRA), blocking tumor cell proliferation and angiogenesis. Often administered in combination with chemotherapy like doxorubicin to enhance antitumor effects. Investigated for potential use in other cancers expressing PDGFRA, including certain gliomas and gastrointestinal stromal tumors. Also utilized as a reference standard in laboratory research and antibody development due to its well-characterized binding properties.